Healthcare · Drug Manufacturers - General
Each rating is built from the measures listed beneath it. Values are the latest reported figures; the rating beside each one is how that measure scores on our −100 to +100 scale.
Debt levels, liquidity and how solid the balance sheet looks.
| Debt to equity | 1.28 × | -94 |
| Current ratio | 1.32 × | +29 |
| Quick ratio | 0.74 × | -10 |
| FCF / Total debt | 0.28 × | +34 |
| Buybacks vs new shares | Bought back $5.1B of its own shares last year (≈1.4% of its market value) | +34 |
Margins, and the returns being earned on the capital employed.
| Gross margin | 75.9 % | +92 |
| Operating margin | -0.2 % | -93 |
| Net margin | 4.8 % | -67 |
| Return on equity | 7 % | -27 |
| Gross profit / assets | 35.5 % | +31 |
| Asset turnover | 0.47 × | — |
| Profit vs cash flow | $18.3B profit, generated $16.5B cash | -17 |
The direction and pace of revenue and earnings.
| Revenue growth (YoY) | 5.1 % | +1 |
What you pay relative to what the business actually delivers.
| P/E (trailing) | 117.72 × | -97 |
| Forward P/E | 16.01 × | +45 |
| PEG ratio | 2.73 × | -74 |
| Price/Book | 8.73 × | -91 |
| Price/Sales | 5.5 × | -4 |
| EV/EBITDA | 13.9 × | +14 |
| FCF yield | 4.1 % | +2 |
| Sector | Healthcare |
| Industry | Drug Manufacturers - General |
| Market cap | $366.0B |
| Dividend yield | 2.37% |
| Payout ratio | 266.67% |
| Beta | 0.22 |
Merck & Co., Inc. operates as a healthcare company worldwide. It offers human health pharmaceutical for various areas under the Keytruda, Keytruda Qlex, Welireg, Gardasil, ProQuad, M-M-R II, Varivax, Vaxneuvance, Capvaxive, RotaTeq, Pneumovax 23, Bridion, Prevymis, Dificid, Zerbaxa, Winrevair, Adempas/ Verquvo,…
The figures above were captured on 20 October 2026. Open MRK in StockDecks for the current numbers, plus the four ratings it doesn't show here — Hype, Analyst Upside, Trend Signals and Insider Track — all free.
Premium adds the Full Score and Custom Score, which combine these fundamentals with the other ratings into a single number.